Cancer cells have long been adept at evading the watchful eye of the immune system, but a recent study from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has uncovered a novel mechanism that sheds light on this elusive process. The research, published in Science Immunology, identifies RNA helicase DDX6 as a previously unrecognized 'hidden switch' that prevents the immune system from recognizing cancer cells, potentially paving the way for more effective cancer immunotherapies.
The immune system is constantly on the lookout for abnormal cells, including cancer cells, and one of its key warning signals is double-stranded RNA (dsRNA), which is produced naturally within cells. These molecules resemble RNA produced during viral infections, triggering the innate immune system, the body's first line of defense against foreign or abnormal cells. However, many cancer cells suppress these warning signals, allowing them to grow unnoticed.
Previous studies have shown that ADAR1, an enzyme that edits RNA, helps regulate how cells respond to dsRNA. This study, led by Associate Professor Polly Chen, Deputy Director and Principal Investigator of CSI Singapore, identified the RNA helicase DDX6 as a previously unrecognized suppressor of dsRNA sensing. DDX6 works in conjunction with ADAR1 to suppress these natural danger signals, reducing immune activation triggered by endogenous dsRNA and making cancer cells less visible to the immune system.
This discovery provides new insights into how anti-tumor immune responses are regulated. Assoc Prof Chen explains, 'Cancer cells are remarkably good at hiding from the immune system. Our study uncovered a previously unknown mechanism that helps them stay hidden. By targeting DDX6, we may be able to remove this 'cloak' and enable the immune system to recognize and attack cancer more effectively.'
The research challenges a long-held view of RNA editing, which previously believed that RNA editing generally weakened dsRNA structures, making them less likely to trigger immune responses. Instead, the CSI Singapore team found that certain RNA editing events can strengthen dsRNA structures, enhancing their ability to activate the body's natural immune defenses. DDX6 prevents these beneficial RNA editing events from occurring, aiding in the escape of tumors from immune attack.
This new understanding of how RNA editing regulates immune sensing in cancer fundamentally changes how researchers think about RNA editing and its role in regulating immunity. Dr. Larry Ng, the first author of the paper, remarks, 'What surprised us most was that the biology did not behave the way we expected. For years, researchers believed RNA editing generally weakened these immune-triggering RNA molecules. Instead, we found that certain RNA editing events can actually strengthen them.'
The discovery of this novel mechanism of cancer immune evasion highlights DDX6 as a potential new target for cancer immunotherapy. Targeting this pathway could help overcome cancer-associated immunosuppression and potentially improve the effectiveness of existing cancer immunotherapies. In laboratory studies, removing DDX6 restored immune signaling and slowed tumor growth by making cancer cells more visible to the immune system.
The research team is now working on identifying molecules that block DDX6 and investigating their ability to enhance anti-tumor immune responses. They also plan to identify additional proteins involved in this newly discovered pathway and determine how they contribute to cancer-associated immunosuppression. These efforts could lead to the discovery of additional therapeutic targets that could strengthen anti-tumor immunity.
This study not only opens up exciting new possibilities for developing cancer therapies but also changes our understanding of how RNA editing regulates immune responses, offering a deeper insight into the complex world of cancer biology and the immune system's intricate dance with cancer cells.
